Longwood Fund

  • About
  • Portfolio
  • People
  • Press
  • Investor Login
  • Industry Events
  • About
  • Portfolio
  • People
  • Press
  • Investor Login
  • Industry Events

Axial Therapeutics Announces Key R&D Promotions to Advance Clinical and Preclinical Pipeline of Small Molecule Microbiome Therapeutics

March 30, 2023

Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update

March 27, 2023

TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies

March 21, 2023

Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors

March 20, 2023

TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones

March 8, 2023

Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330

February 27, 2023
« Older Entries

Longwood Fund

The Prudential Tower

800 Boylston Street
Suite 1715
Boston, MA, 02199

  • About
  • Portfolio
  • People
  • Press
  • Investor Login
  • Industry Events

© Longwood Fund. All Rights Reserved